1Cersosmio RJ. Irinotecan: a new antineoplastic agent for the management of colorectal cancer[J].Ann Pharmacother,1998, 32(12) :1324 - 1333.
2Rivory LP, Chatelut E; Canal P ,et al. Kinetics of the in vivo inter-conversion of the carboxylatee and lactone forms of irinoteacan (CPT-11) and of its metabohte SN-38 in patients[J]. Cancer Res,1994, 54(24):6330-6333.
3Ratain MJ. Insights into the phamacokinetics and pharmacodynamics of irinotecan[J]. Clin Cancer Res. 2000, 6(9) : 3393 - 3394.
4De Bruijn P, Verweij J,Loos WJ,et al.Determination of irinotecan(CPT-11 )and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection[J]. Chromatogr B Biomed Sci Appl, 1997, 698 ( 1/2 ) : 277-228.
5Escoriaza J, Aldaz A, Castellanos C,et al. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid Chromatography: application to clinical pharmacokinetic studies[J]. J Chromatogr B Biomed Sci Appl . 2000. 740(2) :159-168.
6Ragot S, Marquet P, Lachatre F,et al.Sensitive determination of irinotecan (CVF-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry [ J]. J Chromatogr B Biomed Sci Appl,1999, 7.36(1/2) : 175 - 184.
7Saita T, Fujito H, Mori M. Development of ELISAs for irinotecan and its active metabolite SN-38[J].Biol Pharm Bull, 2000, 23(8):911-916.
8Chabot GG, Abrigerges D, Catimel G et al. Population pharmacokinetics and pharmacodynamics of irinotecan(CPT-11) and active metabolite SN-38 during phase Ⅰ trials[J]. Arm Oncol, 1995, 6(2) : 141 - 151.
9Ma MK, McLeod HL.Lessons learned from the metabolic pathway[J]. Curr Med Chem, 2003, 10(1):41 - 49.
10Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis[J]. Cancer Res, 2000, 60(24):6921 -6926.
